CAMILLA (G/E Cohort) Trial

[Slide 1] CALYPSO: Phase II study investigating savolitinib in combination with durvalumab in advanced papillary renal cancer. Papillary (PRC) cohort: Savolitinib 600mg OD os follow up n=41 Patients with: starting D1 Primary endpoint cRR Advanced papillary RCC Measurable disease as + Key secondary endpoints: per RECIST v1.1 PFS VEGF naive/treatment Durvalumab 1500mg 4 OS DoR refractory weekly added D29 Best response at 24weeks ECOG 0-1 Safety Treatment until progression or loss of clinical cRR in ITT: 32% benefit. Follow up 2 years cRR in MET-driven: 53% Median FU: 14.1months (CI: 7.4 - 28.4) ctDNA ctDNA ctDNA ctDNA (baseline) (week 4) (week 4-16) (PD) No new safety signals Suarez et al, JCO,2023 ASCO Genitourinary Dr Francesca Jackson-Spence ASCO AMERICAN SOCIETY OF #GU25 PRESENTED BY: CUNICAL ONCOLOGY Cancers Symposium Presentation is property of the author and ASCO for reuse contact cermissions@asco.org KNOWLEDGE CONQUERS CANCER --- [Slide 2] 5 Final PFS and os in ITT population ITT population Progression-Free Survival ITT population Overall Survival 100 100 75 6.5 months 18.3 months 75 (95% CI: 2.73-11.99) (95% CI: 7.26-30.65) 50 50 25 25 0 0 0 6 12 18 24 30 36 42 48 54 60 66 72 78 0 6 12 18 24 30 36 42 48 54 60 66 72 78 Time from enrolment (months) Time from enrolment (months) ASCO Genitourinary PRESENTED BY: Dr Francesca Jackson-Spence #GU25 ASCO AMERIC AN SOCIETY OF CLINICAL ONCOLOGY Cancers Symposium Presentation is property of the author and ASCO Permission required for reuse contact permissione@asco KNOWLEDGE CONQUERS CANCER --- [Slide 3] Final PFS and os in MET-driven population 6 MET-driven Progression-Free Survival MET-driven Overall Survival Non-MET-driven MET-driven Non-MET-driven MET-driven (n=17) (n=15) (n=17) (n=15) Median os Median PFS 13.9 27.4 12.3 2.9 Mo (95% CCI) Mo (95% CCI) -(95% CI: 2.86-23.82) (95% CI: 9.27-34.73) (95% CI:3.15-30.65) (95% CI: 0.95. 9.7) 100 100 (96) 75 HR 0.25 (66) 75 HR 0.73 (95% CI: 0.10-0.64) so (95% CI: 0.34-1.57) 50 of 50 Possession 25 Processing 25 0 0 0 6 12 18 24 30 36 42 48 54 60 66 72 78 0 6 12 18 24 30 36 42 48 54 60 66 72 78 Time from enrolment (months) Time from enrolment (months) nths) ASCO Genitourinary PRESENTED BY: Dr Francesca Jackson-Spence ASCO AMERICAN SOCIETY OF #GU25 CLINICAL ONCOLOGY Cancers Symposium Presentation is property of the author and ASCO Permission required for reuse contact ong KNOWLEDGE CONQUERS CANCER --- [Slide 4] Conclusions Phase Il study shows savolitinib + durvalumab combination has activity in papillary renal cancer Tumour responses enriched in the MET-driven group with median os 27.4 months Response irrespective of PD-L1 status and TMB status 48% were ctDNA positive at baseline ctDNA status at baseline has prognostic value Few patients had trackable MET alterations The promising efficacy and safety profile for savolitinib in combination with durvalumab in MET-driven PRC is further investigated in the SAMETA trial (NCT05043090). ASCO Genitourinary #GU25 PRESENTED BY: Dr Francesca Jackson-Spence ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY Cancers Symposium Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.